– USA, VA – Perthera, the premier personalized medicine service company, today announced that Andrew Mignatti, an executive leader in pathology, laboratory and diagnostic areas, has now joined the company as chief executive officer. In his role, Mignatti will be responsible for strategic organization of the company’s collaborative management culture and implementation of plans to navigate growth. Among other initiatives, he will be working closely with the leadership team to create awareness of Perthera’s individualized therapy options for patients during the critical stages of their cancer journey.
“As a personalized medicine leader, Perthera is painting the picture of how all oncologists will soon challenge the standard of care and manage their patient’s cancer treatments – and I’m honored to now be a part of it,” says Mignatti. “The diagnostic landscape is running rampant with organizations that focus exclusively on genomic testing, but Perthera truly differentiates itself with its unique multi-omic approach to metastatic disease. As the sole company to pair proteomics and phosphoproteomics with targeted genomic analysis and an expert medical review, I fully believe Perthera is equipped with not only the right expertise but the right methodology to lead this charge.”
Mignatti joins the company from his role as senior vice president of operations at RedPath, a Pittsburgh-based molecular diagnostics laboratory focused on providing novel solutions for clinicians. In that position, he was responsible for the financial growth and operations of the company, overseeing all revenue and customer operations, as well as marketing and laboratory functions. Mignatti was integral in the sale of RedPath to PDI, Inc., a leading healthcare commercialization company, in Nov. 2014.
With more than 15 years of experience in the pathology, laboratory and diagnostic fields, Mignatti also previously worked with Esoterix, Inc. and LabCorp. He graduated from Saint Edward University in Austin, Texas and is also a graduate of the National Outdoor Leadership School.
“Andrew’s undeniable ambition and business-savvy in this field is exactly what Perthera needs at this crucial stage in our company’s growth,” says Dendy Young, chairman and co-founder of Perthera. “We’re more than excited to have Andrew lead our committed team of renowned clinical and scientific professionals as we bring multi-omic testing to the center stage in this fight against cancer and aggressively rewrite the clinical status quo. His contributions will help drive our efforts to enable oncologists to provide the best possible treatment options for their patients.”
Perthera, based in McLean, Va, is the premier personalized medicine service company. As the only organization to combine the latest multi-omic molecular profiling, including genomic, proteomic and phosphoproteomic analysis, with a patient’s medical history and state-of-the-art diagnostic technology, Perthera enables oncologists to deliver precision medicine to treat an individual patient’s unique cancer.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.